Company intelligence / Profile preview

PharmExtracta S.p.A

Ownership: Private
Development stage: Commercial

Overview

PharmExtracta has developed numerous products validated by clinical studies published in scientific journals. Their probiotic Bactoblis was awarded at the Nutraingredients Awards as Finished Product of the Year in the "Immune Support" category in 2015, and their Crispact formulation was a finalist in CPhI Pharma Awards in 2021[3].

Therapeutic areas: ImmunologyOtherGastroenterologyCardiovascularWomen's Health
Modalities: PhytotherapyProbioticsNutraceuticals
Industry: Food & Nutrition

Drug pipeline

2 assets

Berberol

Commercial

Indications: Metabolic disorders

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on PharmExtracta S.p.A.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PharmExtracta S.p.A.

Explore the full profile